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ABSTRACT
Background Asthma and chronic obstructive pulmonary
disease are airway inflammatory diseases characterised
by airflow obstruction. Currently approved
bronchodilators such as long-acting b2 adrenoceptor
agonists are the mainstay treatments but often fail to
relieve symptoms of chronic obstructive pulmonary
disease and severe asthma and safety concerns have
been raised over long-term use. The aim of the study
was to identify the receptor involved in prostaglandin
E2 (PGE2)-induced relaxation in guinea pig, murine,
monkey, rat and human airways in vitro.
Methods Using an extensive range of pharmacological
tools, the relaxant potential of PGE2 and selective agonists
for the EP1e4 receptors in the presence and absence of
selective antagonists in guinea pig, murine, monkey, rat
and human isolated airways was investigated.
Results In agreement with previous studies, it was found
that the EP2 receptor mediates PGE2-induced relaxation of
guinea pig, murine and monkey trachea and that the EP4
receptor mediates PGE2-induced relaxation of the rat
trachea. These data have been confirmed in murine
airways from EP2 receptor-deficient mice (Ptger2). In
contrast to previous publications, a role for the EP4
receptor in relaxant responses in human airways in vitro
was found. Relaxant activity of AH13205 (EP2 agonist) was
also demonstrated in guinea pig but not human airway
tissue, which may explain its failure in clinical studies.
Conclusion Identification of the receptor mediating
PGE2-induced relaxation represents a key step in
developing a novel bronchodilator therapy. These data
explain the lack of bronchodilator activity observed with
selective EP2 receptor agonists in clinical studies.
INTRODUCTION
Asthma and chronic obstructive pulmonary disease
(COPD) are inﬂammatory diseases of the airway
characterised by airﬂow limitation. The Global
Burden of Disease Study1 has projected that COPD,
which ranked sixth as the cause of death in 1990,
will become the third leading cause of death
worldwide by 2020. Globally, approximately 300
million people have asthma, which is the most
common chronic disease in children.2 3
Currently, the majority of patients with inﬂam-
matory diseases of the airway are treated with
a combination of long-acting b agonists (LABAs)
and corticosteroids, but signiﬁcant issues exist with
these therapies, particularly LABAs. While long-
and short-acting b agonists help to provide patients
with short-term relief from airﬂow limitation, they
do little to treat the underlying pathology.
Furthermore, since the introduction of LABAs,
there has been increasing concern that their use
may be associated with an increased risk of death
from asthma.4
A number of clinical studies have reported
beneﬁcial effects of inhaled prostaglandin E2 (PGE2)
on airway calibre in normal subjects5e8 and in
patients with chronic bronchitis and asthma.5 9 10
In addition, PGE2 has anti-inﬂammatory properties
in patients with asthma,9 11 providing an ideal dual
therapy for the treatment of these diseases. Despite
the beneﬁts of inhaled PGE2, the development of
prostanoid agonists for the treatment of airway
inﬂammatory diseases has been hindered as pros-
tanoids induce irritancy of the upper airway
resulting in a reﬂex cough.11 PGE2 can act on
a number of receptors, so it was hoped that the
beneﬁcial bronchodilator and anti-inﬂammatory
effects could be dissociated from the airway irri-
tancy to provide a novel therapeutic target.
There are currently nine known prostanoid
receptors. PGE2 has relatively low afﬁnity for the
FP, IP, TP, DP and CRTh2 receptors and acts
predominantly via the EP receptors. The EP
receptors have been subclassiﬁed into EP1, EP2,
EP3 and EP4 (encoded by Ptger1ePtger4 genes),12e14
and distinct signalling pathways initiate diverse
and opposing downstream effects in different
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tissues.13e15 Several investigators have documented bronchodi-
lator activity in vitro and in vivo in a wide range of species
including guinea pigs, mice and humans, and it has been
suggested that EP2 receptor activation is responsible for PGE2
activity.16e19 However, a selective EP2 receptor agonist
(AH13205) with a promising preclinical proﬁle did not appear to
have any bronchodilator activity in man.16 Previous studies have
been hampered by the lack of selective pharmacological tools.
We now have a wide range of tool compounds and, by adopting
a pharmacological approach and prostanoid receptor-deﬁcient
mice, we provide substantial evidence that, although the EP2
receptor mediates PGE2-induced relaxation in several species, it is
in fact the EP4 receptor that mediates relaxation of human
airways. This is an important ﬁnding which could lead to the
development of a new class of bronchodilator therapy.
METHODS
Male C57BL/6 mice (18e20 g), Dunkin-Hartley guinea pigs
(300e500 g) and Cynomolgus (Cyno) monkey (Macaca fascicu-
laris) tissue were purchased from Harlan (Bicester, Oxon, UK)
and male Sprague Dawley rats (250e275 g) were purchased
from Charles River (Margate, UK). EP receptor gene-deleted mice
were originally provided by Dr Shuh Narumiya, Kyoto Univer-
sity and breeding colonies were maintained at Imperial College,
London. Human airway samples (trachea, major bronchus,
secondary bronchi) were obtained from donor patients (n¼8, 3
male) or recipients (emphysema, n¼5, 2 male; cystic ﬁbrosis,
n¼3, 1 male) for lung transplants performed at the Royal
Brompton or Hareﬁeld Hospital. Approval was obtained from
the Royal Brompton and Hareﬁeld ethics committee after
receiving the relevant consent from patients and relatives.
The trachea (apart from murine) was opened longitudinally
by cutting through the cartilage directly opposite to the smooth
muscle layer. Unless stated otherwise, the epithelium was left
intact and transverse segments were prepared and sutured in
order to be suspended from steel hook transducers in 10 ml baths
containing KrebseHenseleit (KH) solution warmed to 378C and
bubbled with 95% O2/5% CO2. Indomethacin (10 mM), a non-
selective COX inhibitor, was present in KH solution in all
experiments to prevent the production and release of endoge-
nous prostanoids. Changes in force were measured isometrically
using force displacement transducers connected to a data
acquisition system as previously described.20
Carbachol (CCh; 1 mM) was used to induce increased tension in
tissues over a 30 min period before the addition of any antagonists
or their appropriate vehicles which were incubated for a further
30 min. This concentration of CCh was required to produce
approximately 80% of the supramaximal response to 1 mM ACh
in all species. Cumulative concentrationeresponse curves were
then constructed using the relevant drugs and subsequently, at
the end of the experiment, the non-speciﬁc phosphodiesterase
inhibitor papaverine (100 mM) was used to assess the maximum
capacity for relaxation of each tissue. For experiments on smaller
airways, third to fourth generation bronchi (1e2 mm diameter)
were dissected and sutured as described. For these experiments,
a higher concentration of CCh (10 mM) was necessary to induce
the required level of increased tension.
Full details are given in the online supplement.
Data analysis and statistics
Data are expressed as mean6SEM of n independent
observations. Concentrationeresponse curves were analysed by
non-linear regression using the PRISM curve-ﬁtting program to
produce curves of best ﬁt, from which EC50 values were subse-
quently derived. Estimates of antagonist afﬁnity were calculated
using the equation pKB¼log (CR  1)  log [B] as described by
Gaddum,21 where CR is the concentration ratio calculated from
the EC50 of agonist in the presence of the antagonist divided by
the EC50 of the agonist alone, KB is the equilibrium dissociation
constant and [B] is the concentration of antagonist. In the
experiments described here, the term pA2 is substituted for pKB
as antagonists were used at one concentration only, which
precludes assumptions being made about the nature of the
antagonism.
RESULTS
Effect of PGE2 on guinea pig tracheal strips
Under basal levels of tension (basal tone), increasing concen-
trations of PGE2 (0.1 nMe10 mM) resulted in a biphasic response
producing a pronounced contraction at lower concentrations
(35.464.0% of the maximum contraction to ACh, 10 mM) that
was later attenuated by increasing the concentration of PGE2 in
the bath (ﬁgure 1A). This contractile response was completely
absent in the presence of the EP1 antagonist GW848687X
(1 mM). This was then conﬁrmed using selective EP receptor
agonists, with the EP1 selective agonist ONO-D1-004 being the
most potent and effective at inducing contraction of the guinea
pig trachea (ﬁgure 1B).
When tension was induced in the guinea pig trachea using
CCh (1 mM) (induced tone), increasing concentrations of PGE2
(0.1 nMe10 mM) produced substantial relaxation (69.167.3% of
the maximum relaxation to 100 mM papaverine). Due to the
apparent contractile actions of PGE2 via the EP1 receptor, PGE2-
induced relaxation in guinea pig trachea was performed in the
presence of GW848687X (1 mM). Under these conditions,
compared to its vehicle control, addition of AH6809 (10 mM) to
the bath before the administration of PGE2 antagonised the
relaxation produced (ﬁgure 1C), resulting in a rightward shift in
the curve (pA2¼5.7) commensurate with an action at the EP2
receptor (previous studies report antagonist afﬁnities of
approximately 5.9e6.3).22e24 Subsequently, the response to
PGE2 was also assessed in the presence of selective antagonists
for EP3, EP4, IP and FP receptors (L-826266, 1 mM; GW627368X,
1 mM; RO3244794, 10 mM; and AL-8810, 10 mM, respectively).
Compared with their vehicle controls, addition of these antag-
onists did not produce any effect on PGE2-induced relaxation in
guinea pig tracheal strips (ﬁgures not shown). When increasing
concentrations of each EP receptor agonist (0.1 nMe1 mM) was
applied to guinea pig tissue, only the EP2 agonist ONO-AE1-259
induced substantial relaxation (52.863.62% of the maximum
relaxation to 100 mM papaverine) (ﬁgure 1D). These data,
alongside the AH6809 data, indicate that the EP2 receptor
mediates PGE2-induced relaxation in guinea pig trachea consis-
tent with previous data.16
Effect of PGE2 on murine tracheal segments
In contrast to the guinea pig, the addition of increasing
concentrations of PGE2 to mouse tracheal tissue under basal
tone failed to produce a contractile response (data not shown).
However, when applied to murine tracheal segments under
induced tone, PGE2 induced a substantial relaxation response in
the tissue (92.663.1% of the maximum response to 100 mM
papaverine) (ﬁgure 2A). This response to PGE2 observed in tissue
taken from C57BL/6 wild type mice was then compared with
that produced in tissue from prostanoid receptor gene-deﬁcient
mice. Of the gene-deleted tissues tested (deﬁcient for EP1, EP2,
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EP3, EP4, IP, FP, DP1 or TP receptors), only the response of
tracheal segments taken from Ptger2 (EP2)-deﬁcient mice
differed substantially from tissue taken from wild type equiva-
lents (ﬁgure 2C,D). The relaxation response produced by PGE2 in
Ptger2/ tracheal tissue was substantially reduced (24.566.6%
of the maximum response to 100 mM papaverine), indicating
that PGE2-induced relaxation in mouse tracheal tissue is largely
dependent on EP2 receptors. Furthermore, AH6809 antagonised
PGE2-induced relaxation in mouse tracheal segments under
induced tone, producing a rightward shift in the curve (pA2¼5.9)
commensurate with afﬁnity at the EP2 receptor (ﬁgure 2B).
Interestingly, there was a small reduction in the relaxation
produced by PGE2 in IP receptor-deﬁcient tissues (72.065.8% of
the maximum response to 100 mM papaverine vs 85.961.8% for
the wild type control), possibly indicating a minor role for the IP
receptor in PGE2-induced relaxation in mouse tracheal segments.
The maximum contractile responses to ACh and the maximum
relaxation responses to papaverine were not changed in the
prostanoid receptor deﬁcient animals.
Effect of PGE2 on rat tracheal strips
PGE2 (1 nMe10 mM) did not induce a contractile response in rat
tracheal strips under basal tone. However, under induced tone,
PGE2 produced a concentration-dependent relaxation although
Figure 1 Involvement of prostanoid
EP receptors in prostaglandin E2 (PGE2)-
induced contraction and relaxation of
guinea pig tracheal strips. (A) Inhibition
of PGE2-induced contraction under
basal tone by the EP1 antagonist
(GW848687X, 1 mM) (PGE2 + the
appropriate vehicle (filled circle) or
GW848687X in the presence of PGE2
(square), n¼4e6). (B) Response to
selective EP receptor agonists under
basal tone (ONO-D1-004 (filled circle),
ONO-AE1-259 (circle), ONO-AE-248
(filled square) and ONO-AE1-329
(square)¼EP1e4 respectively, n¼4). (C)
Inhibition of PGE2-induced relaxation
under induced tone by AH6809 (10 mM,
EP1/EP2/DP antagonist), (PGE2 +
vehicle (filled circle), PGE2 + AH6809
(square), n¼4). (D) Response to
selective EP receptor agonists under
induced tone (ONO-AE1-259 (circle),
ONO-AE-248 (filled square) and ONO-
AE1-329 (square)¼EP2e4 respectively,
n¼4). Data represent mean6SEM.
Figure 2 Involvement of the
prostanoid EP receptors in
prostaglandin E2 (PGE2)-induced
relaxation of murine tracheal segments
under induced tone. (A) PGE2-induced
relaxation (PGE2 (filled circle), ethanol
vehicle control (circle), n¼5). (B)
Inhibition of PGE2-induced relaxation by
AH6809 (10 mM, (EP1/EP2/DP1 receptor
antagonist). (PGE2 + vehicle (filled
circle), PGE2 + AH6809 (square), n¼4).
(C) Effect of specific individual EP
receptor gene deficiency on PGE2-
induced relaxation compared with the
respective response elicited in wild-
type tissues (C57BL/6 wild type (filled
circle), Ptger 1/ (square), Ptger 2/
(filled inverted triangle), Ptger 3/
(circle), n¼4). (D) Effect of specific
individual EP receptor gene deficiency
on PGE2-induced relaxation compared
with the respective response elicited in
wild-type tissues (129/Ola 3 C57BL/6
wild type (filled circle), Ptger 4/
(circle), n¼4). Data represent
mean6SEM.
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smaller in magnitude than in other species (31.961.5% of the
maximum response to 100 mM papaverine). EP receptor selective
agonists (1 nMe10 mM) were evaluated and only the EP4 agonist
ONO-AE1-329 caused substantial relaxation (36.764.0% of
maximum relaxation to 100 mM papaverine) (ﬁgure 3A).
Furthermore, two structurally distinct EP4 antagonists inhibited
PGE2-induced relaxation compared with their vehicle control
(0.1% DMSO) (ﬁgure 3B). Both GW627368X (1 mM) and ONO-
AE3-208 (100 nM) produced a substantial rightward shift in the
curve (pA2¼6.560.1 and 8.960.1, respectively) commensurate
with an action at the EP4 receptor (previous studies report
antagonist afﬁnities of approximately 7 and 8.9 for GW627368X
and ONO-AE3-208, respectively25 26). Finally, the effect of
removing the epithelium on the response of rat trachea to ONO-
AE1-329 was investigated. When the responses of tracheal strips
with the epithelium intact were compared with tracheal strips
with epithelial cells removed, there was no substantial difference
in relaxation toONO-AE1-329 (epithelium intact: logEC50¼7.5,
maximum relaxation¼338.3699.7 mg; epithelium removed:
logEC50¼7.6, maximum relaxation¼310.5674.2 mg).
Effect of PGE2 on Cyno monkey tissue
PGE2 produced a concentration-dependent relaxation of induced
tone (53.465.9% of the maximum relaxation response to
100 mM papaverine) (ﬁgure 3C). Of the selective agonists, only
the EP2 selective agonist ONO-AE1-259 caused relaxation
(36.568.0% of the maximum relaxation response to 100 mM
papaverine), therefore indicating that, like guinea pig and mouse,
PGE2-induced relaxation of Cyno monkey trachea appears to be
mediated by the EP2 receptor.
Effect of PGE2 on human airways
PGE2 (0.1 nMe1 mM) failed to produce a contractile response
under conditions of basal tone but produced signiﬁcant relaxa-
tion under conditions of induced tone (62.3% of the maximum
relaxation to 100 mM papaverine; data not shown). For
comparison, the clinically used LABA formoterol produced
73.867.1% of maximum relaxation to papaverine with
logEC50¼8.960.2, consistent with values in previously
published data.27 Of the selective agonists tested, only the EP4
selective agonist ONO-AE1-329 produced a substantial degree of
relaxation (76.268.6% of maximum relaxation to 100 mM
papaverine) (ﬁgure 4A). AH6809 failed to antagonise PGE2-
induced relaxation in human airway samples (ﬁgure 4B).
Furthermore, increasing concentrations of two EP2
agonistsdAH13205 (1010e105 M) and ONO-AE1-259
(1 nMe10 mM)dfailed to produce any signiﬁcant relaxation
(ﬁgures 4A and 5B). In experiments on human tissue we used
the tool compound with the most optimal proﬁle with regard to
antagonist afﬁnity and selectivity (ONO-AE3-208).26 The EP4
antagonist ONO-AE3-208 (100 nM) inhibited both PGE2- and
ONO-AE1-329-induced relaxation (pA2¼8.060.2 and 8.760.3,
respectively; ﬁgure 4C,D). Experiments comparing PGE2 with
ONO-AE3-208 in human tissue were conducted in the presence
of SQ29548 (TP antagonist, 1 mM) to prevent PGE2-induced
contraction via TP receptors. The relaxation response to ONO-
AE1-329 was also tested against an alternative non-muscarinic
spasmogen. In the presence of 10 mM histamine-induced tone,
ONO-AE1-329 still produced substantial relaxation
(63.4619.6% of maximum relaxation to papaverine,
logEC50¼7.660.5). To ensure the EP4-induced relaxation was
not speciﬁc to larger airways and not subject to regional differ-
ences in the airways, the effect of PGE2, ONO-AE1-259 and
ONO-AE1-329 was measured in smaller calibre airways (third to
fourth generation bronchi, 1e2 mm diameter). Responses in
these airways were similar to those seen in trachea/primary
bronchi with PGE2 and ONO-AE1-329 producing relaxation
(PGE2: 43.165.4% of maximum relaxation to papaverine,
logEC50¼7.2 (n¼2); ONO-AE1-329: 32.165.0% of maximum
relaxation to papaverine, logEC50¼7.660.1 (n¼3)), with
ONO-AE1-259 having no substantial effect.
Finally, in order to conﬁrm that the biological activity of
AH13205 was similar to that observed in previous studies, we
demonstrated its relaxant activity in guinea pig trachea studies
(ﬁgure 5A).16 However, this relaxant activity was not parallelled
in human airway tissue, which may explain its failure in clinical
studies (ﬁgure 5B).
DISCUSSION
Inhaled b2 adrenoceptor agonists are currently the gold standard
bronchodilators prescribed to patients with respiratory diseases
such as asthma and COPD. While long- and short-acting
b agonists help to provide patients with short-term relief from
airﬂow limitation, they do little to treat the underlying
pathology. Furthermore, since the introduction of LABAs, there
has been increasing concern about their safety, particularly when
used as monotherapy.4 For these reasons, the search is on for
Figure 3 Involvement of the prostanoid EP receptors in prostaglandin E2 (PGE2)-induced relaxation of rat tracheal strips and monkey airway samples
under induced tone. (A) Response of rat tracheal strips under induced tone to selective EP receptor agonists (ONO-D1-004 (filled circle), ONO-AE1-259
(circle), ONO-AE-248 (filled square) and ONO-AE1-329 (square)¼EP1e4 respectively, n¼3). (B) Inhibition of PGE2-induced relaxation of rat tracheal
strips by ONO-AE3-208 (100 nM) and GW627368X (1 mM) (PGE2 in the presence of the appropriate vehicle (filled circle), PGE2 in the presence of ONO-
AE3-208 (square) or GW62768X (circle), n¼4). (C) Response of Cyno monkey airway samples under induced tone to selective EP receptor agonists
(ONO-D1-004 (filled circle), ONO-AE1-259 (circle), ONO-AE-248 (filled square) and ONO-AE1-329 (square)¼EP1-4, respectively, and PGE2 (filled
triangle), n¼3). Data represent mean6SEM.
1032 Thorax 2011;66:1029e1035. doi:10.1136/thx.2010.158568
Airway biology
alternative bronchodilator therapies which have an increased
safety proﬁle. Identiﬁcation of a safe therapeutic agent which
also possesses anti-inﬂammatory activity would make for an
extremely attractive alternative to LABAs.
PGE2 causes relaxation of animal28 and human17 29 isolated
airway smooth muscle. Inhaled PGE2 is a bronchodilator in
animals,18 29 30 normal subjects5e8 and in patients with chronic
bronchitis and asthma.5 9 10 In addition, PGE2 has anti-
inﬂammatory properties in patients with asthma,9 11 providing
an ideal dual therapy for the treatment of these diseases.
Despite the beneﬁts of inhaled PGE2, the development of
prostanoid agonists for the treatment of airway inﬂammatory
diseases has been hindered as prostanoids induce irritancy of the
upper airway resulting in a reﬂex cough.11
We recently identiﬁed the EP3 receptor as being responsible for
PGE2-induced airway irritancy (in human, guinea pig and
murine in vitro assays) and in a guinea pig cough model, so an
opportunity exists to ﬁnd a therapeutic agent devoid of this
sensory irritant side effect if alternative receptors are identiﬁed
as being responsible for the bronchodilator activity.31 Several
investigators have documented bronchodilator activity both in
vitro and in vivo in a wide range of species including guinea pigs,
mice and humans, and it has been suggested that EP2 receptor
activation is responsible for this activity.16e19 However, a selec-
tive EP2 receptor agonist (AH13205) with a promising preclinical
proﬁle did not appear to have any bronchodilator activity in
man.16 Recently, however, improved tools have become available
(selective ligands and prostanoid receptor-deﬁcient mice) so, in
the light of the issues with current bronchodilators, it seemed
pertinent to revisit this area of research.
To investigate which receptor PGE2 acts to cause airway
smooth muscle relaxation, a range of selective tools were tested
on constricted isolated trachea tissue from guinea pigs, mice,
monkeys, rats and humans. In all species PGE2 caused
a concentration-dependent relaxation of airway smooth
muscle. Experiments using selective ligands on guinea pig,
monkey and mouse tissue identiﬁed the EP2 receptor as
mediating this response, which is consistent with previous
studies.16e19 This was further conﬁrmed using mice deﬁcient in
individual prostanoid receptors, in that the response to PGE2
present in wild-type animals was substantially diminished in
Pgter2/ mice, again conﬁrming previous data.18 19 30 In
contrast, but consistent with previous data, PGE2-induced
relaxation of rat isolated tracheal smooth muscle was mediated
via activation of the EP4 receptor.32
In contrast, the data from human tissue studies clearly showed
that PGE2-induced relaxation is mediated via the EP4 and not the
EP2 receptor. This conclusion is based on the in vitro relaxant
activity of the selective EP4 receptor agonist (ONO-AE1-329) and
the lack of activity of the selective EP2 receptor agonists (ONO-
AE1-259, AH13205) in human airways. A role for the EP4
compared with the EP2 receptor was also substantiated by the
lack of effect of AH6809 (EP1/2/DP receptor antagonist) and the
effectiveness of the EP4 antagonist (ONO-AE3-208) in inhibiting
PGE2-induced relaxation of human airway smooth muscle. These
data are in contrast to a previous publication describing a role for
the EP2 receptor in PGE2-induced relaxation of human airway
smooth muscle.17 However, there are some differences between
our studies and previous ones which, in the main, can be
explained by the lack of selectivity of the tools available at the
time the previous studies were carried out. Compared with the
study by Norel et al,17 our study has beneﬁted from the use of
optimised, more potent and selective agonists (EP2 receptor
Figure 4 Involvement of EP
prostanoid receptors in prostaglandin E2
(PGE2)-induced relaxation of human
airway smooth muscle under induced
tone. (A) Comparative effects of
selective EP receptor agonists (ONO-
D1-004 (filled circle), ONO-AE1-259
(circle), ONO-AE-248 (filled square) and
ONO-AE1-329 (square)¼EP1e4,
respectively, n¼3e4). (B). PGE2-
induced relaxation was not inhibited in
the presence of AH6809 (EP1/EP2/DP
antagonist, 10 mM) (PGE2 + vehicle
(filled circle), PGE2 + AH6809 (circle),
n¼8). (C) Inhibition of PGE2-induced
relaxation by ONO-AE3-208 (EP4
antagonist, 100 nM) in the presence of
SQ29548 (TP antagonist, 1 mM) (PGE2
+ vehicle and SQ29548 (filled circle),
PGE2 + ONO-AE3-208 and SQ29548
(square), n¼4). (D) Inhibition of ONO-
AE1-329 (EP4 agonist)-induced
relaxation by ONO-AE3-208 (EP4
antagonist, 100 nM) (ONO-AE1-329 +
vehicle (filled circle), ONO-AE1-329 +
ONO-AE3-208 (square), n¼4). Data represent mean6SEM.
Figure 5 Species differences in the response of airway smooth muscle
under induced tone to the EP2 selective agonist AH13205. (A) AH13205-
induced relaxation of guinea pig tracheal strips (n¼6). (B) Response of
human airway smooth muscle to AH13205 (n¼3). Data represent
mean6SEM.
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agonist ONO-AE1-259; EP4 receptor agonist ONO-AE1-329)
compared with misoprostol which is a non-selective agonist at
EP2e4 receptors33 (table 1). Furthermore, we had the opportunity
to use a highly selective EP4 antagonist with greater afﬁnity and
selectivity for the receptor than AH23848B, which was used in
the previous studies and is a weak antagonist at both the EP4 and
TP receptor (pKi 4.9e5.6 and 6.2, respectively), and AH6809,
which was used as an EP2 antagonist but also has afﬁnity at the
EP1 and DP1 receptors (table 1).33 In the paper by Nials et al,16 the
EP2 receptor dependence of the relaxant response (mostly inves-
tigated in non-human species) was suggested by the activity of
misoprostol, AH13205 and butaprost which all have a relatively
weak afﬁnity for the EP2 receptor.16 The relaxant activity of
AH13205 in guinea pig trachea described in the study by Nials
et al was reproduced in our studies, suggesting that the lack of
effect on human airway relaxation was a real phenomenon. The
absence of relaxant activity on human airway smooth muscle
preparations also provides a likely explanation for the poor
efﬁcacy of the EP2 receptor agonist in clinical trials as a bron-
chodilator in humans.16
Interestingly, it would appear that, of all the animal species
tested, PGE2-induced relaxation of human airway smooth
muscle and the role of the EP4 receptor was most accurately
represented in the rat. The responses in non-human primate
tissue were not representative of those in human tissue, given
the EP2 receptor dependence of the relaxant response to PGE2.
This would imply that bioassay of rat tissue would be amenable
for medium throughput screening if drug discovery programmes
were initiated in this area, thus limiting the use of valuable
human airway specimens.
In conclusion, we believe that these data show that the EP4
receptor is responsible for PGE2-induced relaxation of human
airway smooth muscle. We recently identiﬁed the EP3 receptor as
being responsible for PGE2-induced airway irritancy and
cough,31 so an opportunity exists to ﬁnd a therapeutic agent
devoid of this sensory irritant side effect liability. However, as
PGE2 also enhances plasma leakage in numerous anatomical sites
via enhanced blood ﬂow,13 it would be prudent to investigate
the receptor responsible as an ideal bronchodilator should not
worsen inﬂammatory exudation or oedema. In summary, EP4
selective compounds could potentially be the next generation of
bronchodilators identiﬁed since the introduction of b2 adreno-
ceptors and anticholinergics more than half a century ago.
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